Barclays
MGX icon

Barclays’s Metagenomi Therapeutics MGX Stock Holding History

Barclays’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3
Closed -$5 – 5518
2025
Q4 		$5 Hold
3
– – ﹤0.01% 5167
2025
Q3 		$7 Hold
3
– – ﹤0.01% 5411
2025
Q2 		$4 Sell
3
-28,845
-100% -$45.2K ﹤0.01% 5175
2025
Q1 		$39.2K Sell
28,848
-13,633
-32% -$32.5K ﹤0.01% 4673
2024
Q4 		$153K Buy
42,481
+33,783
+388% +$81.5K ﹤0.01% 4421
2024
Q3 		$18.9K Buy
8,698
+6,532
+302% +$22.7K ﹤0.01% 4901
2024
Q2 		$8.84K Buy
+2,166
New +$14.9K ﹤0.01% 4530

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's MGX Position: Q1 2026 in Review

Barclays sold out of Metagenomi Therapeutics (MGX) in Q1 2026, closing a stake of 3 shares — an estimated $5 sold.

Barclays first reported a position in MGX in Q2 2024 and held it in 7 quarters. The position peaked at $153K in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Barclays reported no remaining Metagenomi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 3 Metagenomi Therapeutics shares in Q1 2026, an estimated $5.
  • Barclays first reported a position in Metagenomi Therapeutics in Q2 2024 and held it in 7 quarters.
  • Barclays's Metagenomi Therapeutics position peaked at $153K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.